Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know

Código QR

Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know

Guardado en:

Detalles Bibliográficos
Autor principal:	Felipe Martínez
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d80ba3ca3c0d4fe485081691a10cf167
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

What cardiologists need to know about cardiovascular magnetic resonance (CMR)
por: J. Cameron Bridgman, et al.
Publicado: (2017)

A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
por: Tariq Ahmad, et al.
Publicado: (2021)

Adipositas Cordis or Cor Adiposum: A rarely recognized entity every cardiologist should be aware of!
por: Vijayachandra Y Reddy, et al.
Publicado: (2021)

What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists?
por: Kreton Mavromatis, et al.
Publicado: (2020)

Heart Rate Variability and Cardiovascular Fitness: What We Know so Far
por: Souza HCD, et al.
Publicado: (2021)

GLP-1, SGLT-2, new devices for interventional cardiologists
por: Çetin Erol
Publicado: (2021)

Pregnancy in Women with Congenital Heart Disease: A Guide for the General Cardiologist
por: Catherine R Weinberg, et al.
Publicado: (2020)

Meditation and Cardiovascular Health: What is the Link?
por: Sebastian Schnaubelt, et al.
Publicado: (2019)

Moderate Aortic Stenosis: What is it and When Should We Intervene?
por: Sveeta Badiani, et al.
Publicado: (2021)

Hypertension in Women: Should There be a Sex-specific Threshold?
por: Eva Gerdts, et al.
Publicado: (2021)

What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries
por: Robert Sykes, et al.
Publicado: (2021)

Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
por: Esmee ME Bovee, et al.
Publicado: (2021)

Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials
por: Alberto J Lorenzatti
Publicado: (2021)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Anne Mirjam Kerola, et al.
Publicado: (2021)

Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know?
por: Giandomenico Bisaccia, et al.
Publicado: (2021)

Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
por: Mattia Cattaneo, et al.
Publicado: (2019)

Evaluation of low gradient severe aortic stenosis: should we change our outlook in the analysis of clinical data?
por: Ivan Corazza, et al.
Publicado: (2021)

What is your diagnosis?
por: Uğur Nadir Karakulak, et al.
Publicado: (2021)

What is your diagnosis?
por: Yavuzer Koza, et al.
Publicado: (2021)

Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
por: Jack Wei Chieh Tan, et al.
Publicado: (2021)

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
por: Shahnam Sharif, et al.
Publicado: (2021)

Cardiovascular Pharmacotherapy Focus
por: Pablo Avanzas
Publicado: (2019)

The ISCHEMIA Trial: What is the Message for the Interventionalist?
por: Emmanuel Ako, et al.
Publicado: (2021)

Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology Service
por: Hasan Ali Farhan, et al.
Publicado: (2021)

Cerebrovascular ischemic event - what about the coronaries
por: Joseph C. Lee, et al.
Publicado: (2021)

Inflammation and Cardiovascular Disease: The Future
por: Natalie Arnold, et al.
Publicado: (2021)

The Effect of Testosterone on Cardiovascular Disease and Cardiovascular Risk Factors in Men: A Review of Clinical and Preclinical Data
por: Hargun Kaur, et al.
Publicado: (2021)

What Cannot be Missed: Must-read Papers, 2018
por: Demosthenes G Katritsis
Publicado: (2019)

What Cannot Be Missed: Important Publications on Electrophysiology in 2019
por: Andrew Grace, et al.
Publicado: (2020)

What Cannot Be Missed: Important Publications on Electrophysiology in 2020
por: Sanjiv M Narayan, et al.
Publicado: (2021)

COVID-19 Pandemic and Cardiovascular Disease
por: Aniket S Rali, et al.
Publicado: (2020)

Deciphering the Riddles in Nutrition and Cardiovascular Disease
por: Amelia Carro, et al.
Publicado: (2019)

The Association Between Psoriasis and Cardiovascular Diseases
por: Ahmed Zwain, et al.
Publicado: (2021)

Effects of aerospace environments on the cardiovascular system
por: Erdinç Ercan
Publicado: (2021)

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Alberto J Lorenzatti, et al.
Publicado: (2020)

Viscoelastic Haemostatic Assays in Cardiovascular Critical Care
por: Aniket S Rali, et al.
Publicado: (2021)

What is the Real Message of the ISCHEMIA Trial from a Clinician’s Perspective?
por: Islam Y Elgendy, et al.
Publicado: (2020)

Electronic Cigarettes and Cardiovascular Risk: Caution Waiting for Evidence
por: Domenico D’Amario, et al.
Publicado: (2019)

Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
por: Aarti Thakkar, et al.
Publicado: (2021)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Chris Wai Hang Lo, et al.
Publicado: (2021)